Exploring the challenges of accessing medication for patients with cystic fibrosis

Sophie Herbert, Nicola Jane Rowbotham, Sherie Smith, Patrick Wilson, Zoe C Elliott, Paul A Leighton, Alistair Duff, Alan Robert Smyth

Abstract
Reducing treatment burden in cystic fibrosis (CF) is the top research priority for patients and clinicians. Difficulty accessing medication is one aspect of treatment burden. We investigated this with an online survey available globally for patients with CF and healthcare professionals. Almost three quarters of patients with CF in our survey report difficulty getting repeat prescriptions on time, and most community pharmacists experience interrupted supplies of CF-specific medications. These barriers affect emotional and physical health of people with CF. Two-thirds of people with CF would like to get all their CF medication from one place, their CF centre.

Introduction
Reducing treatment burden for patients with cystic fibrosis (CF) was voted the number one research priority by people with CF (pwCF), their parents/carers and healthcare professionals in a James Lind Alliance Priority Setting Partnership. ‘Treatment burden’ describes the increased workload associated with healthcare affecting individuals’ physical and psychological well-being. The James Lind CF2 project further explored this research priority.

CF is a multisystem disease requiring complex treatment including specialist medications (eg, inhaled antibiotics and CFTR modulators) and non-specialist drugs (eg, bronchodilators and multivitamins), the former being drugs that are used almost exclusively in the treatment of pwCF, which are usually prescribed by the CF team. High treatment burden is common to many chronic diseases, resulting in reduced adherence, wasted medication, health deterioration and poorer quality of life.

Treatment burden for pwCF is considerable—most spend around 2 hours per day on treatment. Accessing prescribed medications is an issue for patients with chronic diseases, which contributes to treatment burden. We aimed to review the obstacles pwCF encounter when accessing medications and to demonstrate insight from professionals who provide medications (pharmacists and primary care doctors).

Methods
The James Lind CF2 project explores in depth some of the research priorities identified by the James Lind Alliance priority setting partnership for CF. It is supported by the UK National Institute for Health Research and the UK CF Trust. An online survey for pwCF was conducted generating free-text data on accessing medications. A further survey for primary care doctors and community pharmacists (with guidance from a focus group) was distributed using SurveyMonkey and was available for 4 weeks in June 2019. Both quantitative ‘single answer’ and qualitative ‘free text’ questions were incorporated. A final questionnaire to pwCF (July 2019) asked; ‘should all medication be accessed from secondary care?’.

The questionnaires were not country-restricted and were promoted via social media. They were anonymous; no personal data were stored, or financial incentive given. All responses to the questionnaires were non-compulsory. Data were downloaded into Excel for quantitative analysis and into NVivo for qualitative analysis. Prior to commencing this work, we published our protocol at: https://nottingham-repository.worktribe.com/output/2226944.

Results
James Lind CF2 question ‘Do you ever have difficulties getting the medications you need from your GP/Pharmacist/hospital/homecare?’ found 76% (241/317) of pwCF had difficulty accessing medication. The demographics of the participants have previously been published. Of the pwCF who had difficulty accessing medication, 65 participants expanded with a free-text response following from the quantitative question. Six recurring themes were identified (figure 1). Emotive language was used in free-text responses describing challenges that pwCF experienced in accessing their medication (figure 2).

The healthcare professionals’ survey yielded 256 responses, including 249 from the UK. Almost a third of respondents did not have pwCF in their cohort (31%; 78/249), with the majority having one or two pwCF 45% (114/249). Primary care doctors accounted for 16% of the responses (40/249). Data on prescribing revealed that 39% (13/33) lacked confidence when prescribing CF specialist medication and 50% (17/34) had been asked to prescribe medication that should be prescribed by secondary care. Suggestions on how the CF centre can support primary care included education, ensuring up-to-date guidelines and having access to discuss care. Many pwCF did not see value from primary care doctors’ input, and some primary care doctors felt that their role was ‘limited as there is such good access to specialists’. However, others perceived their role to be caring for the pwCF outside of the CF condition, ‘including mental health, contraception and vaccinations’.

Community pharmacists describe their role as a medication dispenser to ensure continuous treatment
Brief communication

**Figure 1** Quotations from pwCF and their families for each theme identified. pwCF, people with cystic fibrosis; GP, general practitioner (primary care doctor).

Difficulties obtaining medication supplies are reported by 55% (52/94) of community pharmacists, including pancreatic enzyme replacement therapy, dornase alfa, CF-specific vitamin preparations and colistimethate sodium. ‘Supply problems are a major issue, this is not a pharmacy problem but industrial pharmaceutical companies causing the delay’. Some specialist medications have a quota restricting supply, ‘for example, a manufacturer restricts supply to 2 per month, but you have a script for 12’. Expensive medications with short shelf-lives are not kept in stock because of the potential for waste if treatment is changed. For routine repeat prescriptions, 48% (95/196) of pharmacies require 1–2 days’ notice. For specialist medication, 39% (75/196) of pharmacies require 3–4 days’ notice with 10% (19/196) requiring 1–2 weeks’ notice. Only 40% (76/192) of these have online repeat prescription requests.

**DISCUSSION**

We present a complex process undertaken by pwCF to access medication, including 76% of those surveyed expressing

**Figure 2** Inner flow chart depicts the journey to accessing medications where the patient does not have a chronic, multisystem disease. The outer circle is a pathway described by the CF patient group that they take to access medications 2. Emotive language used by the patient group to describe the cycle in 1. CF, cystic fibrosis; NHS, National Health Service.

**Figure 3** Should all medications be accessed from secondary care? Responses from the CF population, Community pharmacists and primary care. 1. For those that answered ‘no’ if travel was not an issue, would they change their mind? 2. For primary care doctors who said ‘no’, how many were confident at prescribing. CF, cystic fibrosis.

of pharmacies require 1–2 days’ notice. For specialist medication, 39% (75/196) of pharmacies require 3–4 days’ notice with 10% (19/196) requiring 1–2 weeks’ notice. Only 40% (76/192) of these have online repeat prescription requests.

PwCF and healthcare professionals were asked whether all medications should be prescribed and accessed in secondary care (figure 3). Overall, 63% (25/40) pwCF wanted to access medication from secondary care. Reservations included travel distance, car parking and hospital pharmacy delays.

**DISCUSSION**

We present a complex process undertaken by pwCF to access medication, including 76% of those surveyed expressing...
difficulty getting repeat prescriptions from primary care. Our data suggest that this is part of the high treatment burden impacting on physical and mental health.

Although each group interviewed has specific difficulties and frustrations, all are agreed on the need to simplify the process. Research shows that patients with chronic diseases have difficulty accessing medication, issues including pharmacy stock, medication errors and short durations of prescriptions—all issues raised in our study. This is exacerbated by the number of medications pwCF take (average 8 daily).8

Primary care doctors and community pharmacists describe the barriers to accessing medication including practitioners’ lack of familiarity with specialist medication and interrupted supplies. A guide to improving the logistics of obtaining medicines in the community offers pwCF and their families, practical suggestions on how to reduce such difficulties.9 Primary care doctors suggested that better communication with the CF centre and accessible guidelines would support their prescribing. The UK National Health Service long-term plan (2019) aims for electronic prescribing,10 which may improve communication between the CF centre and primary care.

Our study has limitations. Respondents were self-selected and those with negative experiences might be more motivated to participate. We did not survey CF centres. Not every respondent answered every question. The patient with CF cohort responding to ‘Should all medication be accessed from secondary care?’ was a smaller group than the James Lind CF2 initial survey. We did not enquire as to whether a delivery service would aid access to medications. The surveys were conducted prior to the COVID-19 pandemic, which might have altered responses, if patients were apprehensive about the infection risk in attending hospital. The strengths include the global reach and large number of responses to our original survey (941 responses from 21 countries).1

CONCLUSION
Accessing medication is a problem for pwCF adding to the high treatment burden, impacting on both the emotional and physical health. The next step is for targeted quality improvement plans to help reduce treatment burden.

Twitter Nicola Jane Rowbotham @nicrowbotham

Contributors SH, NJR, SS, ARS were involved in concept, design, data collection, analysis and preparing the final manuscript. PW and ZCE involved in the data collection, analysis and preparing the final manuscript. PAL involved in analysis and preparing the final manuscript. AD involved in preparing the final manuscript.

Funding This work was funded by the UK Cystic Fibrosis Trust, and the University of Nottingham. NJR was an NIHR Academic Clinical Fellow at University of Nottingham. ARS is part of the National Institute for Health Research Nottingham Biomedical Research Centre.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval Faculty of Medicine & Health Sciences Research Ethics Committee deemed this work not to require ethical approval on 30 April 2019.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iDs
Sophie Herbert http://orcid.org/0000-0002-0106-1003
Nicola Jane Rowbotham http://orcid.org/0000-0003-1105-3645
Alan Robert Smyth http://orcid.org/0000-0001-5494-5438

REFERENCES
1 Rowbotham NJ, Smith S, Leighton PA, et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax 2018;73:388–90.
2 Alsadah A, van Merode T, Alhammari R, et al. A systematic literature review looking for the definition of treatment burden. Heliyon 2020;6:e03641.
3 Mair FS, May CR. Thinking about the burden of treatment. BMJ 2014;349:g6680.
4 Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8:91–6.
5 Davies G, Rowbotham NJ, Smith S, et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. J Cyst Fibros 2020;19:499–502.
6 Lowton K, Ballard KD. Adult cystic fibrosis patients’ experiences of primary care consultations: a qualitative study. Br J Gen Pract 2006;56:518–25.
7 Wilson PM, Kataria N, McNeilly E. Patient and carer experience of obtaining regular prescribed medication for chronic disease in the English National health service: a qualitative study. BMC Health Serv Res 2013;13:192.
8 Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012;47:523–33.
9 Duff AJ, Havermans T, Smith B. Improving self-management and adherence through interaction between the multidisciplinary team, the patient, and their families. In: Bentley S, Castellani C, Peckham D, et al, eds. Optimizing pharmaceutical care in cystic fibrosis. European Cystic Fibrosis Society, 2020: 233–49.
10 NHS. The NHS long term plan, 2019. Available: https://www.longtermplan.nhs.uk/ [Accessed Oct 2019].